Core Viewpoint - Lexicon Pharmaceuticals is celebrating its 30th anniversary as a biopharmaceutical company and will ring the Nasdaq Stock Market Closing Bell on January 27, 2026, highlighting its commitment to developing therapies for serious cardiometabolic diseases and chronic neuropathic pain [1][2]. Company Overview - Lexicon Pharmaceuticals focuses on pioneering medicines that transform patients' lives, leveraging a strong scientific foundation in genomics to support its drug pipeline [2][3]. - The company has developed a unique genomics target discovery platform, Genome5000™, which has studied nearly 5,000 genes and identified over 100 protein targets with significant therapeutic potential [3]. Pipeline and Development - Lexicon has a promising pipeline of drug candidates in various stages of discovery and development, targeting conditions such as neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, and metabolism [3].

Core Viewpoint - Lexicon Pharmaceuticals, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, showcasing its advancements in biopharmaceuticals and innovative medicines [1]. Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [2]. - The company utilizes the Genome5000™ program, a unique genomics target discovery platform, to study nearly 5,000 genes and identify over 100 protein targets with significant therapeutic potential across various diseases [2]. - Lexicon has successfully advanced multiple medicines to market and has a robust pipeline of drug candidates in discovery and clinical and preclinical development, targeting conditions such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [2].

Group 1 - Lexicon Pharmaceuticals will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3 and the Evercore Healthcare Conference on December 4 [1] - The events will be accessible via the Company's website for live viewing and replays [1] Group 2 - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [2] - The Genome5000™ program has enabled Lexicon to study nearly 5,000 genes, identifying over 100 protein targets with significant therapeutic potential [2] - The company has advanced multiple medicines to market and has a pipeline of drug candidates in various stages of development for conditions such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [2]

Group 1 - Lexicon Pharmaceuticals will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on November 18, 2025 [1] - The event will be accessible live and via replays on the company's website [1] Group 2 - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [2] - The company has developed a unique genomics target discovery platform called Genome5000™, studying nearly 5,000 genes and identifying over 100 protein targets with therapeutic potential [2] - Lexicon has multiple medicines on the market and a pipeline of drug candidates in various stages of development for conditions such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [2]

Core Insights - Lexicon Pharmaceuticals, Inc. will release its third quarter 2025 financial results on November 6, 2025, prior to market open [1] - A conference call and live webcast will be held at 8:30 a.m. ET on the same day to discuss the financial results and provide a business update [1][2] Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [3] - The company utilizes its Genome5000™ program to study nearly 5,000 genes, identifying over 100 protein targets with significant therapeutic potential across various diseases [3] - Lexicon has advanced multiple medicines to market and has a pipeline of drug candidates in discovery and clinical and preclinical development for conditions such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [3]

Company Overview - Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [3] - The company utilizes its Genome5000™ program to study nearly 5,000 genes, identifying over 100 protein targets with significant therapeutic potential across various diseases [3] - Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in areas such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [3] Upcoming Events - Company management will participate in a fireside chat at Citi's Biopharma Back to School Conference on September 3 at 1:45 p.m. ET [1] - The company will also present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 3:00 p.m. ET [1] - Live events and replays of the presentations will be accessible via the company's Events page on its website [2]

Group 1 - Lexicon Pharmaceuticals has regained compliance with Nasdaq Listing Rule 5550(a)(2) as its common stock has maintained a closing bid price of $1.00 or greater for ten consecutive business days [1] - The update regarding compliance was previously disclosed in the Company's Current Report on Form 8-K filed on July 28, 2025 [1] Group 2 - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [2] - The company utilizes its Genome5000™ program to study nearly 5,000 genes, identifying over 100 protein targets with significant therapeutic potential across various diseases [2] - Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in areas such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [2]

Company Announcement - Lexicon Pharmaceuticals, Inc. will release its second quarter 2025 financial results on August 6, 2025, prior to market open [1] - Management will conduct a conference call and live webcast at 8:30 a.m. ET on the same day to discuss the financial results and provide a business update [1] Conference Call Details - Participants can access the conference call live via webcast on the Company's website [2] - Those wishing to ask questions may register to receive dial-in numbers and a unique pin to join the call [2] - An archived version of the webcast will be available on the Lexicon website [2] Company Overview - Lexicon is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [3] - The Genome5000™ program has enabled Lexicon scientists to study nearly 5,000 genes, identifying over 100 protein targets with significant therapeutic potential [3] - The company has advanced multiple medicines to market and has a pipeline of promising drug candidates in various therapeutic areas including heart failure, neuropathic pain, obesity, cardiology, and diabetes [3]

Group 1 - Lexicon Pharmaceuticals will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on June 5 at 12:50 p.m. ET [1] - The event will be accessible live and as a replay on the Company's website [1] Group 2 - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [2] - The Genome5000™ program has enabled Lexicon to study nearly 5,000 genes, identifying over 100 protein targets with significant therapeutic potential [2] - The company has advanced multiple medicines to market and has a pipeline of drug candidates in various stages of development for conditions such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [2]

Group 1 - Lexicon Pharmaceuticals will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20, 2025, at 9:30 a.m. ET [1] - The event will be accessible live and as a replay on the company's website [1] Group 2 - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [2] - The company has developed a unique genomics target discovery platform called Genome5000™, studying nearly 5,000 genes and identifying over 100 protein targets with therapeutic potential [2] - Lexicon has advanced multiple medicines to market and has a pipeline of drug candidates in various stages of development for conditions such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [2]